MTAI-1025 (NRF2)

About Montai Therapeutics

Montai Therapeutics is a Flagship Pioneering company applying artificial intelligence and machine learning to unlock a novel chemical space for small molecule drug discovery. Its core innovation is the CONECTA platform, which maps over a billion curated 'Anthromolecule' analogs to complex disease biology, aiming to deliver precise, orally available drugs for chronic conditions. The company has built a pipeline targeting validated pathways in inflammation and immunology, with its first program, MTAI-1025, on track for a First-in-Human study in 2026. Montai represents a convergence of next-generation AI, unique chemistry, and a focus on high-unmet-need chronic diseases.

Therapeutic Areas